Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.25 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 1680
Sealed predictions
- COPG2 in dopamine neurons, braak-0.28 (p 0.472) → +0.10 (p 0.790)receipt 1686
Swarm cases
receipt 1686: COPG2 in dopamine neurons, braak
- power
- full sample +0.06 (p 0.807, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.00 (p 0.997, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.976, n 18). could be the mix.
- skeptic
- leave-one-out range -0.05 to +0.21, sign flips 3; without severely affected donors +0.06 (p 0.807, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for COPG2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts